Literature DB >> 30483377

A case report of human tularemia from Iran.

Mahdi Rohani1,2, Behzad Mohsenpour3, Ahmad Ghasemi2,4, Saber Esmaeili2,4, Mohammad Karimi5, Heinrich Neubauer6, Herbert Tomaso6, Ehsan Mostafavi2,7.   

Abstract

Tularemia is one of the most contagious bacterial infections. Here, we report a human case of glandular tularemia in Iran following the first report in 1980. The patient was a 6-year-old girl who had consumed a hunted hare in Kurdistan Province in western Iran.

Entities:  

Keywords:  Francisella tularensis; Hare; Iran; Tularemia

Year:  2018        PMID: 30483377      PMCID: PMC6243145     

Source DB:  PubMed          Journal:  Iran J Microbiol        ISSN: 2008-3289


INTRODUCTION

Francisella tularensis is a Gram-negative bacterium and the causative agent of tularemia, which is regarded as one of the most important zoonotic bacterial diseases worldwide (1). This agent can infect more than 200 species of vertebrates and may be transmitted to humans by ingestion of contaminated water or food, handling infected animals, arthropod bites, or inhalation of contaminated aerosols (2). Farmers, veterinarians, hunters, and medical health workers are among the people at greatest risk of infection (1). Tularemia is widely spread throughout the northern hemisphere. Some of the neighboring countries of Iran such as Turkey, Kazakhstan, Turkmenistan and Russia report tularemia cases annually (3–5). In 1969 and 1970, tularemia was reported in domestic and wild animals from the northwest (Azerbaijan province) and southeast (Zabol County) of Iran (6). The first and only human case of tularemia in Iran was reported in 1980 in Marivan County, Kurdistan Province (7). Following the establishment of the National Reference Laboratory of Plague and Tularemia in 2011 in the Pasteur Institute of Iran, tularemia surveillance was increased throughout the country. Serological surveys among high-risk human populations demonstrated 14.4% and 6.5% seroprevalence of the disease in the west (Kurdistan Province, 2011) and east of Iran (Sistan and Baluchestan Province, 2012), respectively (8, 9). Seropositive rodents were also reported in two studies from Kurdistan (2013) and Sistan and Baluchestan (2013) provinces (10). Due to the emerging prevalence of F. tularensis in Kurdistan Province, educational programs were initiated to increase awareness of physicians for the disease and to consider tularemia in their differential diagnosis. This paper reports F. tularensis infection in a patient in Kurdistan Province following the consumption of meat of a hunted hare in 2017.

Case study

In February 2017 a 6-year-old girl from a village near Marivan City in Kurdistan Province was admitted to a hospital in Sanandaj County, Kurdistan Province. Four days after consuming the meat of a hunted hare, rashes appeared on her body, forearm, and legs; however, 2 hrs later, these rashes disappeared without leaving any lesions or scars. At time of admission, she had no signs of fever, nausea, vomiting, or a sore throat. She had mild lymph-adenopathy of the axillary lymph nodes. Based on the epidemiological history (consuming meat of a hunted hare and living within an area with previous reports of tularemia) and clinical signs (lymph-adenopathy and rash), the patient was hospitalized, considered as a suspected case of tularemia and gentamicin was administrated after taking a blood sample. Sonographic examination revealed that the liver was larger than normal (130 mm in the Medio clavicular line). Kidneys (78 mm in length), spleen, and gallbladder were normal. The blood culture of the hospital laboratory was negative after 48 h of incubation. Urine culture was also negative. The sample was sent to the Pasteur Institute of Iran for molecular and serological detection. In the biochemical examination, the concentration of BS, K+, and BUN was normal but Cr (0.5) and Na+(132) values were lower than normal. ESR, WBC, Hb, and PTT were normal but CRP was positive (1+). Serology and molecular detection were performed in the reference laboratory for tularemia. In the first step, the rapid test VIRAPID® TULAREMIA strip (Vircell, Spain) was used and then the IgM and IgG reactions were quantified in two paired samples taken with 21-day intervals with ELISA (Virion-Serion, Germany). According to the WHO guideline for tularemia (11), a single serum/plasma specimen with a positive ELISA titer is presumptive for F. tularensis. In this case, IgM titer (24 and 21 U/ml, respectively) was positive in both samples. For molecular detection, DNA was extracted from a blood sample using the QIAamp DNA Mini Kit (Qiagen, Germany) and the ISFtu2 real-time PCR was applied. This gene is present in the F. tularensis genome in various copy numbers (12) and the assay; therefore, is suitable for detection of the presence of this bacterium in blood samples. After positive results, the presence of the fop-A gene was examined to confirm the presence of F. tularemia (Fig. 1). The sequence of primers and probes, described previously, were ISFtu2F, TTGGTAGATCAGTTGGTAGGATAACC, ISFtu2R TGAGTTTTATCCTCTGACAACAATATTTC, ISFtu2P FAM-AAAATCCATGCTATGACTGATGCTTTAGGTAATCCA-TAMRA and fopA-F AACAATGGCACCTAGTAATATTTCTGG, fopA-R CCACCAAAGAACCATGTTAAACC, fopAP FAM-TGGCAGAGCGGGTACTAACATGATTGGT-TAMRA by amplification sizes of 97 and 87 bp, respectively. The DNA of F. tularensis subsp holarctica NCTC 10857 was used as a positive control. The amplified product of the ISFtu2 gene was sequenced and compared with the GenBank database. After 2 days of gentamicin administration, the child left the hospital with a good general condition and alleviated symptoms.
Fig. 1.

The amplification plots of the ISFtu2 real-time PCR assay. A: melting curve of ISFtu2 PCR. B: Quantification plots of ISFtu2 PCR.

The amplification plots of the ISFtu2 real-time PCR assay. A: melting curve of ISFtu2 PCR. B: Quantification plots of ISFtu2 PCR.

CONCLUSION

This report of tularemia from the Kurdistan Province was the first human case of tularemia since 1980 from this region (7). Recent serological surveys of human and animal populations have indicated presence of tularemia in this area (9). Some further studies on environmental water samples of the region have also shown that F. tularensis is endemic in this province (data not published). Lack of tularemia reports over a period of 37 years can be due to an insufficient systematic surveillance system to monitor the bacteria in humans, animals, and the environment. According to our report, it seems that the healthcare guidelines for tularemia should be revised and physicians and laboratory staff must be made aware of the circulation of this agent in the area. For this purpose, some rapid tests can be made available for local and regional laboratories as well. Further work is needed to identify current reservoirs, modes of transmission, and the biotype of F. tularensis circulating in this region. Moreover, it is expected that more human cases in Kurdistan Province will be found soon by implementing more educational programs for all physicians and healthcare workers to improve their awareness level about the disease.
  9 in total

1.  First detection of tularaemia in domestic and wild mammals in Iran.

Authors:  A Arata; H Chamsa; A Farhang-Azad; O Mescerjakova; V Neronov; S Saidi
Journal:  Bull World Health Organ       Date:  1973       Impact factor: 9.408

Review 2.  The status of tularemia in Europe in a one-health context: a review.

Authors:  G Hestvik; E Warns-Petit; L A Smith; N J Fox; H Uhlhorn; M Artois; D Hannant; M R Hutchings; R Mattsson; L Yon; D Gavier-Widen
Journal:  Epidemiol Infect       Date:  2014-09-30       Impact factor: 4.434

Review 3.  Tularaemia in Europe: an epidemiological overview.

Authors:  Arne Tärnvik; Heidi-Sabrina Priebe; Roland Grunow
Journal:  Scand J Infect Dis       Date:  2004

Review 4.  Tularemia: history, epidemiology, pathogen physiology, and clinical manifestations.

Authors:  Anders Sjöstedt
Journal:  Ann N Y Acad Sci       Date:  2007-03-29       Impact factor: 5.691

5.  Serological survey of tularemia among butchers and slaughterhouse workers in Iran.

Authors:  Saber Esmaeili; Behzad Esfandiari; Max Maurin; Mohammad Mehdi Gouya; Mohammad Reza Shirzadi; Fahimeh Bagheri Amiri; Ehsan Mostafavi
Journal:  Trans R Soc Trop Med Hyg       Date:  2014-06-18       Impact factor: 2.184

Review 6.  Re-emergence of tularemia in Turkey.

Authors:  Halis Akalin; Safiye Helvaci; Suna Gedikoğlu
Journal:  Int J Infect Dis       Date:  2008-12-31       Impact factor: 3.623

7.  Seroepidemiological survey of tularemia among different groups in western Iran.

Authors:  Saber Esmaeili; Mohammad Mehdi Gooya; Mohammad Reza Shirzadi; Behzad Esfandiari; Fahimeh Bagheri Amiri; Manijeh Yousefi Behzadi; Omid Banafshi; Ehsan Mostafavi
Journal:  Int J Infect Dis       Date:  2013-10-02       Impact factor: 3.623

Review 8.  Tularemia, a re-emerging infectious disease in Iran and neighboring countrie.

Authors:  Afsaneh Zargar; Max Maurin; Ehsan Mostafavi
Journal:  Epidemiol Health       Date:  2015-02-22

9.  Complete genomic characterization of a pathogenic A.II strain of Francisella tularensis subspecies tularensis.

Authors:  Stephen M Beckstrom-Sternberg; Raymond K Auerbach; Shubhada Godbole; John V Pearson; James S Beckstrom-Sternberg; Zuoming Deng; Christine Munk; Kristy Kubota; Yan Zhou; David Bruce; Jyothi Noronha; Richard H Scheuermann; Aihui Wang; Xianying Wei; Jianjun Wang; Jicheng Hao; David M Wagner; Thomas S Brettin; Nancy Brown; Paul Gilna; Paul S Keim
Journal:  PLoS One       Date:  2007-09-26       Impact factor: 3.240

  9 in total
  2 in total

1.  The prevalence of Francisella spp. in different natural surface water samples collected from northwest of Iran.

Authors:  Mahdi Rohani; Abdolrazagh Hashemi Shahraki; Ahmad Ghasemi; Saber Esmaeili; Aynur Karadenizli; Ehsan Mostafavi
Journal:  Iran J Microbiol       Date:  2019-02

2.  Francisella tularensis human infections in a village of northwest Iran.

Authors:  Saber Esmaeili; Mahdi Rohani; Ahmad Ghasemi; Mohammad Mehdi Gouya; Simin Khayatzadeh; Ahmad Mahmoudi; Hossein Ahangari Cohan; Anders Johansson; Max Maurin; Ehsan Mostafavi
Journal:  BMC Infect Dis       Date:  2021-03-31       Impact factor: 3.090

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.